The insular cortex (IC) has been reported to be involved in central cardiovascular control. In the present study, we investigated the cardiovascular responses evoked by microinjection of noradrenaline into the IC as well as the central and peripheral mechanisms involved in their mediation. Microinjection of noradrenaline into the IC (3, 7, 10, 15, 30 and 45 nmol/100 nL) caused long-lasting dose-related pressor and bradycardiac responses. The cardiovascular responses evoked by 15 nmol of noradrenaline were blocked by IC pretreatment with WB4101 or 5-methyl-urapidil, selective α 1 -adrenoceptor antagonists. IC pretreatment with either the selective α 2 -adrenoceptor antagonists RX821002 or the β-adrenoceptor antagonist propranolol did not affect noradrenaline cardiovascular responses. Noradrenaline cardiovascular responses were mimicked by microinjection of the selective α 1 -adrenoceptor agonist phenylephrine into the IC, thus reinforcing the idea that α 1 -adrenoceptors mediate cardiovascular responses to noradrenaline microinjected into the IC. The pressor response to noradrenaline microinjection was potentiated by i.v. pretreatment with the ganglion blocker pentolinium and inhibited by i.v. pretreatment with the selective V 1 -vasopressin receptor antagonist dTyr(CH 2 ) 5 (Me)AVP. The bradycardiac response to noradrenaline microinjection into the IC was abolished by pretreatment with either pentolinium or the V 1 -vasopressin receptor antagonist, indicating its reflex origin. In conclusion, our results suggest that pressor response evoked by microinjection of noradrenaline into the IC involve the activation of IC α 1 -adrenoceptors to cause the release of vasopressin into the circulation.
Introduction
It was assumed before the 1960s that rats did not have a cortical structure analogous to the prefrontal cortex of primates (Rose and Woolsey, 1948) . However, Leonard (1969) described projections from the dorsal medial thalamic nucleus to two distinct frontal cortex regions of the rat brain that could be defined as prefrontal cortex. The prefrontal cortex is a limbic region, which integrates sensory and visceral information from peripheral receptors and has been implicated in control of autonomic activity (Anand and Dua, 1956; Delgado, 1960; Neafsey, 1990; Resstel and Correa, 2006) . In rats, the prefrontal cortex has been anatomically divided into two main regions: the lateral prefrontal cortex or insular cortex (IC) and the medial prefrontal cortex (mPFC) (Krettek and Price, 1977; Leonard, 1969) . The IC has been proposed to be involved in cardiovascular regulation (Allen and Cechetto, 1995; Alves et al., 2009a Alves et al., , 2010 Ruggiero et al., 1987) . Its electrical or chemical stimulation has been reported to cause either pressor or depressor responses (Allen and Cechetto, 1995; Hardy and Holmes, 1988; Hardy and Mack, 1990; Ruggiero et al., 1987; Yasui et al., 1991) . Moreover, it has also been reported that the IC modulates baroreflex activity in unanesthetized rats (Alves et al., 2009a,b) .
Cardiovascular responses have been reported after noradrenaline microinjection into medullary structures such as the nucleus of the solitary tract (Zandberg et al., 1979) as well as into supramedullary structures such as the lateral septal area (Scopinho et al., 2006) , the amygdala (Ohta et al., 1991) , hypothalamic nuclei Camargo et al., 1979; Harland et al., 1989) and the bed nucleus of the stria terminalis (BST) (Crestani et al., 2008 . These results suggest that central noradrenergic pathways are involved in cardiovascular control.
There is evidence that noradrenergic terminals are present in the prefrontal cortex (Morrison et al., 1979) . These terminals originate mainly in projections from the locus coeruleus (LC) and play an important role in the regulation of cortical function (Morrison et al., 1979; Sara and Segal, 1991; Ungerstedt, 1971) . Moreover, noradrenergic neurotransmission in the prefrontal cortex has been implicated in modulation of the cardiovascular system in stress-induced situations (Funk and Stewart, 1996) . We have previously reported that such noradrenergic neurotransmission in the IC is involved in the modulation of baroreflex activity (Alves et al., 2009a) . However, the involvement of IC noradrenergic neurotransmission in the control of arterial pressure and heart rate (HR) has never been systematically investigated. Here, we report on the cardiovascular effects evoked by noradrenaline microinjection into the IC. In addition, we studied the subtypes of adrenoceptor activated in the IC as well as the peripheral mechanism involved in the mediation of these cardiovascular effects.
Materials and methods

Animal preparation
Eighty-nine male Wistar rats weighing 230-270 g were used. Animals were kept in the Animal Care Unit of the Department of Pharmacology, School of Medicine of Ribeirão Preto, University of São Paulo. Rats were housed in plastic cages under standard laboratory conditions, with free access to food and water and under a 12 h light/dark cycle (lights on at 06:30 h). The Institution's Animal Ethics Committee approved the housing conditions and experimental procedures (process number: 167/2007) .
Five days before the experiment, the rats were anesthetized with tribromoethanol (250 mg/kg, i.p.). After local anesthesia with 2% lidocaine, the skull was surgically exposed and stainless steel guide cannulas (26 G) were implanted unilaterally in the IC, using a stereotaxic apparatus (Stoelting, Wood Dale, Illinois, USA). Stereotaxic coordinates for cannula implantation in the IC were selected from the rat brain atlas of Paxinos and Watson (1997) and were: antero-posterior = + 11.7 mm from interaural, lateral = 4.0 mm from the medial suture and vertical = − 4.5 mm from the dorsal surface of the skull. Cannulas were fixed to the skull with dental cement and one metal screw. After surgery, the animals were treated with a poly-antibiotic preparation of streptomycins and penicillins (i.m., 0.27 mg/kg, Pentabiotico, Fort Dodge®, Campinas, SP, Brazil) to prevent infection, and with the non-steroidal antiinflammatory flunixine meglumine (2.5 mg/kg, i.m.; Banamine®, Schering Plough, Cotia, SP, Brazil) for post-operative analgesia.
One day before the experiment, the rats were anesthetized with tribromoethanol (250 mg/kg, i.p.) and a catheter (a 4 cm segment of PE-10 heat-bound to a 13 cm segment of PE-50, Clay Adams, Parsippany, NJ, USA) was inserted into the abdominal aorta through the femoral artery, and later used for arterial pressure and HR recording. A second catheter was implanted into the femoral vein for infusion of saline, pentolininum or dTyr(CH 2 ) 5 (Me)AVP. Both catheters were tunneled under the skin and exteriorized on the animal's dorsum. After surgery, the animals were treated with the non-steroidal anti-inflammatory flunixine meglumine (2.5 mg/kg, i.m.) for post-operative analgesia.
Measurement of cardiovascular responses
On the day of the experiment, the arterial cannula was connected to a pressure transducer. Pulsatile arterial pressure of freely moving animals was recorded with a HP-7754A preamplifier (Hewlett Packard, Palo Alto, CA) and an acquisition board (MP100A; Biopac Systems Inc., Santa Barbara, CA) connected to a computer. Mean arterial pressure (MAP) and HR values were derived from the pulsatile arterial pressure recordings and processed on-line. The sampling rate utilized to acquisition of the data was 200 Hz.
Drug injection into the IC
The needles (33 G, Small Parts, Miami Lakes, FL, USA) used for microinjection into the IC were 1 mm longer than the guide cannula and were connected to a 1 μL syringe (7001-KH, Hamilton, Reno, NV, USA) through PE-10 tubing. The needle was carefully inserted into the guide cannula without restraining the animals and drugs were injected in a final volume of 100 nL over a 10 s period.
Experimental protocols
After surgery, animals were kept in individual cages that later were used in their transport to the experimental room. Animals were allowed 60 min to adapt to the conditions of the experimental room, such as sound and illumination, before starting arterial pressure and HR recordings. The experimental room was acoustically isolated and had constant background noise produced by an air exhauster to minimize sound interference within the experimental room. At least another 30 min period of basal recording of MAP and HR was allowed before beginning experiments. Care was taken to start injections only when blood pressure and HR values had stabilized.
2.4.1. Cardiovascular responses to the microinjection of different doses of noradrenaline into the IC of unanesthetized rats Different doses of noradrenaline were microinjected into the IC of unanesthetized rats. The doses used were 3, 7, 10, 15, 30, or 45 nmol in 100 nL (n = 5 for 7, 10, 15 and 30 nmol and n = 4 for 3 and 45 nmol). To plot the dose-response curve, each animal received up to two microinjections of noradrenaline into the IC. The interval between microinjections was 24 h in order to avoid the tachyphylaxis phenomenon and the dose microinjected in the first and second day was different. The ordering of the injections was alternated to randomize experimental variable. For each dose in the curve, it was calculated the mean of the effect produced in different animals. These values were further plotted to produce the dose-effect curves.
The dose of 15 nmol of noradrenaline, that approximates the ED 50 , was used when studying effects of different treatments on the cardiovascular responses to noradrenaline microinjected into the IC. A different group of animals was used to verify a possible tachyphylaxis phenomenon. In this protocol, microinjections of noradrenaline (15 nmol/100 nL, n = 5) into the IC were repeated 30 min apart.
2.4.2. Study of the local adrenoceptor involved on cardiovascular response to noradrenaline microinjection into the IC A group of animals was used to study the IC adrenoceptor involved in noradrenaline responses. Twenty four hours after the first noradrenaline microinjection, different group of animals received artificial cerebrospinal fluid (ACSF) (100 nL, n = 5) (Alves et al., 2009a,b) ; selective α 1 -adrenoceptor antagonists WB4101 (15 nmol/100 nL, n = 5) (Alves et al., 2009a) or 5-methyl-urapidil (15 nmol/100 nL, n = 5); the selective α 2 -adrenoceptor antagonist RX821002 (15 nmol/100 nL, n = 5) (Alves et al., 2009a) or the nonselective β-adrenoceptor antagonist propranolol (15 nmol/ 100 nL, n = 5) (Alves et al., 2009a) injected into the IC. Noradrenaline was again injected into the IC 10 min later. To confirm the involvement of α 1 -adrenoceptor in the mediation of responses to noradrenaline into the IC, the selective α 1 -adrenoceptor agonist phenylephrine (200 nmol/ 100 nL, n = 5) (Correa and Peres-Polon, 1995) was microinjected into the IC of a group of animals.
Study of the peripheral mechanisms involved in the meditation of the cardiovascular responses to noradrenaline microinjected into the IC
A group of rats were used to study the peripheral mechanisms involved in the meditation of the cardiovascular responses to noradrenaline microinjected into the IC. These experiments were also carried out over 2 days. On day 1, noradrenaline (15 nmol/ 100 nL) was microinjected into the IC as control. On the second day, noradrenaline was injected into the IC 10 min after i.v. treatment with saline (n = 5), the ganglion blocker pentolinium (5 mg/kg, n = 5) Moriguchi et al., 1998) or the V 1 -vasopressin receptor antagonist dTyr(CH 2 ) 5 (Me)AVP (50 μg/kg, n = 5) .
Histological determination of the microinjection site
At the end of the experiment, animals were anesthetized with urethane (1.25 g/kg i.p.) and 100 nL of 1% Evan's blue dye was microinjected into the IC as a marker of the microinjection site. Animals were submitted to intracardiac perfusion with 0.9% NaCl followed by 10% formalin. The brains were removed and post-fixed for 24 h at 4°C, and 40-μm sections were cut with a cryostat (CM-1900; Leica, Wetzlar, Germany). Brain sections were stained with 1% neutral red for light microscopic analysis. Microinjection sites were identified in serial sections according to the rat brain atlas of Paxinos and Watson (1997) .
Drugs
Noradrenaline HCl (SIGMA, St. Louis, MO, USA), dl-propranolol (SIGMA); WB4101 (TOCRIS, Ellisvalle, MO, USA); RX821002 (TOCRIS); 5-methyl-urapidil (RBI, Natick, MA, USA) and phenylephrine (SIGMA) were dissolved in artificial cerebrospinal fluid (ACSF), which had the following composition (in mmol/L): 100 NaCl; 2 Na 3 PO 4 ; 2.5 KCl; 1.0 MgCl 2 ; 27 NaHCO 3 ; 2.5 CaCl 2 (pH =7.4). Pentolinium bitartrate (SIGMA), dTyr(CH 2 ) 5 (Me)AVP (Peninsula Laboratories, King of Prussia, PA, USA), tribromoethanol (SIGMA) and urethane (SIGMA) were dissolved in saline (NaCl 0.9%). Flunixine meglumine (Banamine®, Schering Plough, Brazil) and poly-antibiotic preparation of streptomycins and penicillins (Pentabiotico®, Fort Dodge, Brazil) were used as provided.
Statistical analysis
Data are presented as means ± S.E.M. Basal values of MAP and HR before and after pharmacological treatment were compared using paired Student's t-test. Nonlinear regression analysis was used to compare MAP and HR responses after microinjection of different doses of noradrenaline into the IC. Two-way ANOVA for repeated measurements (treatment vs. time) was used to compare effects of the treatments on MAP and HR responses observed after microinjection of noradrenaline into the IC. P b 0.05 was assumed to be statistically significant.
Results
Cardiovascular responses to the microinjection of different doses of noradrenaline into the IC of unanesthetized rats
Microinjection of ACSF (n =5) into the IC did not affect either MAP (97± 1 vs. 100 ±2 mm Hg, t =1.7, P N 0.05) or HR (358±11 vs. 352± 13 bpm, t = 0.3, P N 0.05) baseline values. However, microinjection of noradrenaline (3, 7, 10, 15, 30 and 45 nmol/100 nL) into the IC of unanesthetized rats (basal MAP= 99±1 and basal HR = 369±16, n = 28) caused long-lasting dose-related pressor and bradycardiac responses (Fig. 1) Fig. 2A .
The cardiovascular responses to the microinjection of noradrenaline (15 nmol/100 nL) (n = 5) into the IC were decreased when a second microinjection of noradrenaline was made 30 min later (MAP: F (1,392) = 30, P b 0.0001 and HR: F (1,392) = 32, P b 0.0001) (Fig. 3) . However, responses were not affected when noradrenaline was microinjected 24 h after the first injection (Fig. 3) .
Microinjection of noradrenaline (15 nmol/100 nL) into structures surrounding the IC, such as primary motor cortex (MAP before: 98 ± 3 and after: 99± 3 mm Hg, t = 3, P N 0.05; and HR before: 343 ± 12 and after: 341 ± 12 bpm, t = 1.2, P N 0.05; n = 3) and forceps minor of the Fig. 1 . Changes in mean arterial pressure (ΔMAP) and heart rate (ΔHR) evoked by noradrenaline microinjection (3, 7, 10, 15, 30, or 45 nmol/100 nL) into the IC of unanesthetized rats (n = 5 for 7, 10, 15 and 30 nmol and n = 4 for 3 and 45 nmol). Points represent means and bars the SEM. Dose-response curves were generated by nonlinear regression analysis and were statistically significant (ΔMAP, r 2 = 0.91 and ΔHR, r 2 = 0.92). corpus callosum (MAP before: 96± 1 and after: 100 ± 3 mm Hg t = 1.5, P N 0.05; and HR before: 359 ± 15 and after: 357 ± 17 bpm; t = 0.9, P N 0.05; n = 3) had no effect on either MAP or HR.
3.2. Effect of IC pretreatment with ACSF, WB4101, 5-methyl-urapidil, RX821002 or propranolol on cardiovascular responses to the microinjection of noradrenaline into the IC of unanesthetized rats 3.2.1. ACSF IC pretreatment with ACSF (n = 5) did not affect either the pressor (43 ± 2 vs. 45 ± 3 mm Hg, t = 0.3, P N 0.05) or the bradycardiac (50 ± 2 vs. 49 ± 3 bpm, t = 0.2, P N 0.05) response to noradrenaline microinjected into the IC of unanesthetized rats.
WB4101
The microinjection of the selective α 1 -adrenoceptor antagonist WB4101 (n= 5) into the IC did not affect either MAP (103± 3 vs. 100 ± 3 mm Hg, t=0.6, PN 0.05) or HR (356± 7 vs. 359 ± 11 bpm, t = 0.3; P N 0.05) baseline values. However, cardiovascular responses to the microinjection of noradrenaline into the IC were significantly reduced after IC treatment with WB4101 (Fig. 4A) . Two-way ANOVA indicated a significant effect of IC treatment with WB4101 on cardiovascular effects of noradrenaline (MAP: F (1,392) =278, P b 0.0001; and HR: F (1.392) = 237, P b 0.0001); a significant effect over time (MAP: F (48,392) = 10, P b 0.0001; and HR: F (48,392) = 25, P b 0.0001) and an interaction between treatment and time (MAP: F (48,392) =8, P b 0.0001; and HR: F (48,392) =19, Pb 0.0001) (Fig. 4A) .
5-Methyl-urapidil
The microinjection of the selective α 1 -adrenoceptor antagonist 5-methyl-urapidil (n=5) into the IC did not affect either MAP (95 ± 2 vs. 100±3 mm Hg, t=1.1, PN 0.05) or HR (384 ± 12 vs. 362 ± 11 bpm, t=1, PN 0.05) baseline values. However, cardiovascular responses to the microinjection of noradrenaline into the IC were significantly reduced Fig. 3 . Time course of the change of mean arterial pressure (ΔMAP) and heart rate (ΔHR) evoked by noradrenaline (15 nmol/100 nL) microinjection into the IC 30 min and 24 h after the first microinjection of noradrenaline. Noradrenaline injections were made at time 0. Points represent the mean and bars the SEM; two-way ANOVA followed by Bonferroni's post hoc test. Fig. 4 . Time course of the change of mean arterial pressure (ΔMAP) and heart rate (ΔHR) evoked by noradrenaline (15 nmol/100 nL) microinjection into the IC before or after IC pretreatment with selective α 1 -adrenoceptor antagonists WB4101 (15 nmol/100 nL) or 5-methyl-urapidil. Noradrenaline injections were made at time 0. Points represent the mean and bars the SEM; two-way ANOVA followed by Bonferroni's post hoc test.
after IC treatment with 5-methyl-urapidil (Fig. 4B) . Two-way ANOVA indicated a significant effect of the treatment with 5-methyl-urapidil on cardiovascular effects of noradrenaline (MAP: F (1,392) =74, Pb 0.0001; and HR: F (1.392) =4, Pb 0.0001); a significant effect over time (MAP: F (48,392) = 6, P b 0.0001; and HR: F (48,392) = 4, P b 0.0001) and an interaction between treatment and time (MAP: F (48,392) = 1.5, P b 0.0001; and HR: F (48,392) =1.1, Pb 0.0001) (Fig. 4B) .
RX821002
Microinjection of the selective α 2 -adrenoceptor antagonist RX821002 (n = 5) into the IC did not affect either MAP (99 ± 3 vs. 100±3 mm Hg, t=0.2, PN 0.05) or HR (353 ± 9 vs. 366 ± 12 bpm, t = 2.1, P N 0.05) baseline values. IC pretreatment with RX821002 also did not change cardiovascular responses to the microinjection of noradrenaline into the IC (Fig. 5) . Two-way ANOVA indicated no significant effect of RX821002 on the cardiovascular effects of noradrenaline (MAP: F (1,392) = 0.2, P N 0.05; and HR: F (1.392) = 0.2, P N 0.05), but indicated a significant effect over time (MAP: F (48,392) = 26, P b 0.0001; and HR: F (48,392) = 48, P b 0.0001) (Fig. 5) .
Propranolol
The microinjection of the nonselective β-adrenoceptor antagonist propranolol (n =5) into the IC did not affect either MAP (96±3 vs. 101± 4 mm Hg; t =1.5, PN 0.05) or HR (356± 9 vs. 369± 16 bpm, t =0.9, PN 0.05) baseline values. The IC pretreatment with propranolol also did not change cardiovascular responses to the microinjection of noradrenaline into the IC (Fig. 5) . Two-way ANOVA indicated no significant effect of propranolol on the cardiovascular effects of noradrenaline (MAP: F (1,392) =0.2, PN 0.05; and HR: F (1.392) =2, PN 0.05), but indicated a significant effect over time (MAP: F (48,392) =26, Pb 0.0001; and HR: F (48,392) =51, Pb 0.0001) (Fig. 5) .
Cardiovascular responses to microinjection of phenylephrine into the IC of unanesthetized rats
Microinjection of phenylephrine (n = 5) into the IC (basal MAP: 95 ± 2 mm Hg and basal HR: 373 ± 8 bpm) caused pressor response (ΔMAP = 49 ± 4 mm Hg, t = 9.7, P b 0.05), which was accompanied by bradycardia (ΔHR = − 95 ± 4 bpm, t = 11, P b 0.05). A typical recording showing cardiovascular responses to the microinjection of phenylephrine into the IC of a representative animal is presented in Fig. 2B. 3.4. Effect of i.v. treatment with saline, pentolinium or dTyr(CH 2 ) 5 (Me) AVP on the cardiovascular responses to the microinjection of noradrenaline into the IC 3.4.1. Saline
The i.v. administration of saline (n = 5) did not affect either pressor (43 ± 2 vs. 45 ± 3 mm Hg; t = 0.3, P N 0.05) or bradycardiac (− 50 ± 2 vs. − 49 ± 3 bpm; t = 0.2, P N 0.05) responses to the microinjection of noradrenaline into the IC.
Pentolinium
The i.v. pretreatment with the ganglion blocker pentolinium (n = 5) significantly reduced baseline MAP values (98 ± 3 vs. 68 ± 3 mm Hg, t = 5.7, P b 0.05), but did not affect baseline HR values (364 ± 10 vs. 382 ± 9 bpm; t = 0.8, P N 0.05). Pretreatment with pentolinium potentiated the pressor response evoked by the microinjection of noradrenaline into the IC and blocked the bradycardiac response (Fig. 6) . Two-way ANOVA indicated a significant effect of treatment with pentolinium on the cardiovascular effects of noradrenaline (MAP: F (1.456) =701, Pb 0.0001; and HR: F (1.456) = 852, P b 0.0001); a significant effect over time (MAP: F (56.456) = 52, P b 0.0001; and HR: F (56.456) = 28, P b 0.0001) and an interaction Fig. 5 . Time course of the change of mean arterial pressure (ΔMAP) and heart rate (ΔHR) evoked by noradrenaline (15 nmol/100 nL) microinjection into the IC before or after IC pretreatment with the selective α 2 -adrenoceptor antagonist RX821002 (15 nmol/100 nL) or the nonselective β-adrenoceptor antagonist propranolol (15 nmol/100 mL). Noradrenaline injections were made at time 0. Points represent the mean and bars the SEM; two-way ANOVA followed by Bonferroni's post hoc test. (Fig. 6) .
dTyr(CH 2 ) 5 (Me)AVP
The i.v. pretreatment with the selective V 1 -vasopressin receptor antagonist dTyr(CH 2 ) 5 (Me)AVP (n = 5) did not affect either MAP (102 ± 3 vs. 97 ± 3 mm Hg, t = 1.3, P N 0.05) or HR (368 ± 12 vs. 352 ± 9 bpm, t = 0.6, P N 0.05) baseline values. Cardiovascular responses to the microinjection of noradrenaline into the IC were significantly reduced after i.v. treatment with the V 1 -vasopressin receptor antagonist (Fig. 6) . Two-way ANOVA indicated a significant effect of treatment with dTyr(CH 2 ) 5 (Me)AVP on the cardiovascular effects of noradrenaline (MAP: F (1.392) = 120, P b 0.0001; and HR: F (1.392) = 294, P b 0.0001); a significant effect over time (MAP: F (48.392) = 14, P b 0.0001; and HR: F (48.392) = 29, P b 0.0001) and an interaction between treatment and time (MAP: F (48.392) = 6, P b 0.0001; and HR: F (48.392) = 18, P b 0.0001) (Fig. 6) .
A photomicrograph of a coronal brain section showing a representative microinjection site into the IC is presented in Fig. 7 . A diagrammatic representation modified from Paxinos and Watson (1997) that indicates microinjection sites of ACSF, noradrenaline, WB4101, 5-methyl-urapidil, RX821002 and propranolol into the IC and noradrenaline into areas surrounding the IC is also presented in Fig. 7 .
Discussion
In the present study, we report that noradrenaline microinjection into the IC of unanesthetized rats caused dose-related pressor and bradycardiac responses. These responses were reduced by IC pretreatment with either selective α 1 -adrenoceptor antagonists WB4101 or 5-methyl-urapidil. Moreover, the IC microinjection of the selective α 1 -adrenoceptor agonist phenylephrine evoked pressor and bradycardiac responses similar those observed after noradrenaline microinjection. The systemic treatment with the ganglion blocker pentolinium potentiated the pressor response evoked by noradrenaline and blocked the bradycardiac response, whereas systemic treatment with the selective V 1 -vasopressin receptor antagonist dTyr(CH 2 ) 5 (Me)AVP reduced both pressor and bradycardiac responses to noradrenaline microinjected into the IC.
Noradrenergic neural terminals have been identified in the IC (Ungerstedt, 1971) . These IC innervations are mainly originated from noradrenergic cells grouped in the LC, which is a small noradrenergic nucleus (designated as A6), that contains ≈1500 neurons projecting to several areas of the forebrain, including the IC (Morrison et al., 1979; Ungerstedt, 1971) . The IC noradrenergic synapses are geometrically orderly throughout the lateral neocortex and that organization differs considerably from that of other cortical afferents. Two noteworthy features of the noradrenergic innervation are the high density of fibers throughout all cortical layers and the predominantly tangential orientation of axons within the cortical gray matter (Morrison et al., 1978) .
Previous results, performed in our laboratory, have demonstrated that activation of IC α 1 -adrenoceptors induce an inhibitory influence on the cardiac component of the baroreflex (Alves et al., 2009a) . Moreover, it has been reported that IC noradrenergic neurotransmission modulates the cardiovascular responses associated with stress situations (Funk and Stewart, 1996) . These results provide evidences of a relevant involvement of IC noradrenergic neurotransmission in central cardiovascular control. Therefore, to investigate the subtype of adrenoceptor involved with mediation of cardiovascular responses evoked by microinjection of noradrenaline into the IC, the IC was pretreated with either selective α 1 -adrenoceptor antagonists WB4101 or 5-methyl-urapidil; the selective α 2 -adrenoceptor antagonist RX821002 or the nonselective β-adrenoceptor antagonist propranolol. The local IC pretreatment with either WB4101 or 5-methyl-urapidil significantly reduced the peak and length of the pressor and bradycardiac responses evoked by noradrenaline microinjection into the IC, thus indicating that these responses depend mainly on local α 1 -adrenoceptor. IC pretreatment with either Fig. 6 . Time course of the change of mean arterial pressure (ΔMAP) and heart rate (ΔHR) evoked by noradrenaline (15 nmol/100 nL) microinjection into the IC before or after intravenous pretreatment with pentolinium (5 mg/kg) or dTyr(CH 2 ) 5 (Me)AVP (dTyr, 50 μg/kg). Noradrenaline microinjections were made at time 0. Points represent the mean and bars the SEM; two-way ANOVA followed by Bonferroni's post hoc test.
RX821002 or propranolol did not affect the cardiovascular changes evoked by noradrenaline, thus reinforcing the idea of an involvement of α 1 -adrenoceptor. Therefore, these results suggest a preferential mediation via activation of local α 1 -adrenoceptors on the cardiovascular responses evoked by microinjection of noradrenaline into the IC.
Similar doses of the antagonists WB4101 and RX821002 have been previously used to identify the subtype of α-adrenoceptors which were involved in the mediation of pressor responses to noradrenaline microinjection in specific central nervous system (CNS) structures (Fernandes et al., 2003; Scopinho et al., 2006; Busnardo et al., 2009) . The pressor response to local microinjection of noradrenaline into the mPFC or lateral septal area was blocked by the pretreatment with WB4101, but not by the pretreatment with RX821002, thus suggesting an involvement of local α 1 -adrenoceptors (Fernandes et al., 2003; Scopinho et al., 2006) . On the other hand, pressor response to noradrenaline microinjection into the hypothalamic supraoptic nucleus (SON) was inhibited after local pretreatment with RX821002, but not by treatment with WB4101 , which points to an involvement of α 2 -adrenoceptors. Also, their use allowed us to identify a situation in which both α-adrenoceptors subtypes were involved in the mediation of pressor responses to noradrenaline microinjected into the BST (Crestani et al., 2008) . These observations indicate that the dose of WB4101 and RX821002 used in the present study is selective and effective in demonstrating the predominance of either α 1 -or α 2 -adrenoceptor in responses involving noradrenergic neurotransmission.
To confirm the involvement of local IC α 1 -adrenoceptor on the noradrenaline cardiovascular responses, it was performed in the IC local administration of the selective α 1 -adrenoceptor agonist phenylephrine. The administration of phenylephrine into the IC evoked similar changes on MAP and HR compared to that observed after noradrenaline microinjection, thus reinforcing the idea that α 1 -adrenoceptors mediate cardiovascular responses to noradrenaline microinjected into the IC. It is important to note that the dose of phenylephrine was higher than that of noradrenaline, once that it has been reported that noradrenaline is approximately 10-times more potent than phenylephrine to evoke cardiovascular responses when microinjected in the CNS (Correa and Peres-Polon, 1995) .
Changes in arterial pressure, HR and renal sympathetic nerve activity (RSNA) have been reported after chemical stimulation of the IC (Butcher and Cechetto, 1995) . The IC has been proposed to modulate the sympathetic nervous activity through a mandatory synapse in the ventrolateral medulla, since it was reported that the increase in RSNA evoked by IC stimulation was completely abolished after ventrolateral medulla treatment with the nonselective synapses blocker CoCl 2 (Butcher and Cechetto, 1995; Cechetto and Chen, 1992) . Consequently, the possible involvement of the sympathetic nervous system in the mediation of the pressor response observed after the microinjection of noradrenaline into the IC should be studied.
Systemic pretreatment with ganglion blocker has been traditionally used as a pharmacological tool to reduce sympathetic nervous activity. In the present study, systemic treatment with pentolinium significantly lowered basal levels of arterial pressure, confirming its effectiveness in reducing sympathetic activity. The variation of MAP (ΔMAP) evoked by IC treatment with noradrenaline was enhanced after ganglion blockade. However, the increase on ΔMAP was similar to change in MAP baseline evoked by pentolinium treatment. Therefore, the increase in ΔMAP caused by microinjection of noradrenaline into the IC in pentolinium-treated animals may be attributed to the initial reduction in MAP baseline caused by the ganglion blockade.
Similar increases in pressor responses caused by central injection of noradrenaline were reported after its injection intracerebroventricular (i.c.v.) (Correa et al., 1985) , into the BST , into the SON or into the mPFC (Fernandes et al., 2003) of pentolinium-treated rats, thus suggesting a humoral mediation. Under those conditions, the pressor effect of the central injection of noradrenaline was reported to be caused by vasopressin release into the circulation Correa et al., 1985; Crestani et al., 2007; Fernandes et al., 2003) .
In the CNS α 1 -adrenoceptors have been shown to mediate vasopressin release by cathecolamines both in vitro (Randle et al., 1986; Yamashita et al., 1988) and in vivo (Brooks et al., 1986; Correa and Peres-Polon, 1995; Crestani et al., 2007) . Attempting to verify whether circulating vasopressin was involved in the pressor response to noradrenaline microinjected into IC, we pretreated animals with the selective V 1 -vasopressin receptor antagonist dTyr(CH 2 ) 5 (Me)AVP. This vasopressin antagonist has been previously used to evidence a vasopressin involvement in the mediation of pressor responses caused by noradrenaline microinjections either i.c.v. or into specific CNS structures Correa et al., 1985; Crestani et al., 2007) , as well as after the intraseptal microinjection of acetylcholine (Peres-Polon and Correa, 1994) and the microinjection of L-glu into the diagonal band of Broca or the SON (Busnardo et al., 2007; Tavares and de Aguiar Correa, 2003) . The peak and length of the pressor response to noradrenaline microinjection into the IC were significantly reduced after pretreatment with dTyr(CH 2 ) 5 (Me)AVP, thus indicating that this response is mainly mediated by an action of the vasopressin. Thus, this result suggests that pressor response evoked by microinjection of noradrenaline into the IC involves acute release of vasopressin into the circulation.
The i.v. treatment with either pentolinium or dTyr(CH2)5(Me)AVP abolished the bradycardiac response to noradrenaline microinjected into the IC. Together, these data suggest a vagal baroreflex response, as a consequence of MAP increase. Vasopressin has been reported to cause positive chronotropic effect (Chiba, 1977) , thus reinforcing the idea of a reflex bradycardia. Also, there was a good correlation between MAP increases and bradycardiac responses.
Vasopressin, also known as antidiuretic hormone, is a potent vasoconstrictor (Altura and Altura, 1984; Barer, 1961) . Two different types of hypothalamic neurons, magnocellular and parvocellular, synthesize vasopressin. The magnocellular neurons are mainly located in the SON and paraventricular nucleus (PVN) of the hypothalamus. Each neuron gives rise to a single axon into the posterior pituitary gland, where its neurosecretory endings release vasopressin. Because the capillaries within the pituitary gland lack an effective blood-brain barrier, vasopressin is released in close proximity to the capillaries and easily enters the bloodstream (Leng et al., 1999) . No direct connections were observed between the IC and either the PVN or the SON (Yasui et al., 1991) , thus suggesting the existence of a relay in this pathway. Thus, the IC should be linked to the PVN or SON through an indirect projection. The microinjection of noradrenaline into the BST has been reported to cause pressure and bradycardiac responses, which are mediated by vasopressin release into the circulation (Crestani et al., 2008 Crestani et al., 2009) . Also, neuronal connections have been identified between the IC and the BST (Yasui et al., 1991) , as well as between the BST and the PVN and SON (Dong and Swanson, 2004) . Considering this, the connection between the IC and the hypothalamus could be the BST. However, further studies are necessary to clarify the pathway involved in these responses.
The physiological role of this pressor pathway activated by the microinjection of noradrenaline into the IC is not yet clear. Vasopressin release is stimulated by plasma osmolality increase, arterial pressure decrease and by reduced cardiac filling or changes in blood volume (Goldsmith, 1988) . Therefore, we may hypothesize that a noradrenergic mechanism in the IC can integrate cardiovascular and neuroendocrine control and could take part in fluid balance and cardiovascular adjustments to stress responses. This idea is favored by studies indicating that brainstem noradrenergic cell groups are activated during stress (Chen and Herbert, 1995; Dayas et al., 2001 ).
IC treatment with adrenoceptor antagonists did not affect either MAP or HR baseline values. Thus, although the present study supports the idea that an IC noradrenergic neurotransmission modulates the cardiovascular system, this neurotransmission is not involved in the tonic maintenance of either arterial pressure or HR. These results corroborate previous data indicating no changes in cardiovascular parameters after IC lesions, local synaptic blockade, blockade of glutamate receptors or blockade of adrenoceptors (Alves et al., 2009a,b; Zhang et al., 1998) .
In summary, the administration of noradrenaline into the IC caused pressor responses, which was accompanied by bradycardia in unanesthetized rats. Our data suggest that bradycardiac response is a vagal baroreflex response, as a consequence of MAP increase. Because noradrenaline effects caused by activation of IC α 1 -adrenoceptors were mediated by acute vasopressin release into the circulation, the results suggest that IC noradrenergic neurotransmission plays a role in the neural circuitry that regulates neuroendocrine and cardiovascular responses.
